-+ 0.00%
-+ 0.00%
-+ 0.00%
Compass Pathways Completes FDA Application for COMP360 in Treatment-Resistant Depression
Share
Listen to the news
Compass Pathways Completes FDA Application for COMP360 in Treatment-Resistant Depression
  • Compass Pathways completed its FDA new drug application submission for COMP360 psilocybin to treat treatment-resistant depression.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109020822) on November 09, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending